Anticancer cell therapy with TRAIL-armed CD34+ progenitor cells

Advances in Experimental Medicine and Biology

Volumn 610, Issue , 2008, Pages 100-111

  Carlo Stella, Carmelo ^a   Lavazza, Cristiana ^a   Carbone, Antonino ^b   Gianni, Alessandro M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; CD34 ANTIGEN;

ANTINEOPLASTIC ACTIVITY; CD34 SELECTION; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; ADENOVIRUS; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; BIOLOGICAL THERAPY; BIOSYNTHESIS; CYTOLOGY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; ONCOLOGY;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; STEM CELLS; TISSUE THERAPY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 47949120367     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-73898-7_8     Document Type: Review

References (60)

1. Almasan, A., and Ashkenazi, A. (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14, 337-348.
2. Armeanu, S., Lauer, U. M., Smirnow, I., Schenk, M., Weiss, T. S., Gregor, M., and Bitzer, M. (2003) Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells, but causes severe apoptosis in primary human hepatocytes. Cancer Res. 63, 2369-2372.
3. Ashkenazi, A. (2002) Targeting death and decoy receptors of the tumor-necrosis factor super-family. Nat Rev Cancer. 2, 420-430.
4. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., Mcmurtrey, A. E., Hebert, A., Deforge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. H. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162.
5. Bregni, M., Shammah, S., Malaffo, F, Di Nicola, M., Milanesi, M., Magni, M., Matteucci, R, Ravagnani, F, Jordan, C.T., Siena, S., and Gianni, A. M. (1998) Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. Gene Ther. 5, 465-472.
6. Burger, J. A., and Kipps, T. J. (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their micro-environment. Blood. 107, 1761-1767.
7. Carlo-Stella, C., Lavazza, C., Di Nicola, M., Cleris, L., Longoni, R, Milanesi, M., Magni, M., Morelli, D., Gloghini, A., Carbone, A., and Gianni, A. M. (2006) Antitumor Activity of Human CD34(+) Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-inducing Ligand. Hum Gene Ther. 17, 1225-1240.
8. Chinnaiyan, A. M., Prasad, U., Shankar, S., Hamstra, D. A., Shanaiah, M., Chenevert, T. L., Ross, B. D., and Rehemtulla, A. (2000) Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A. 97, 1754-1759.
9. De Palma, M., Venneri, M. A., Roca, C., and Naldini, L. (2003) Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med. 9, 789-795.
10. Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y, Smith, C. A., and Goodwin, R. G. (1997) The novel receptor TRAIL-R4 induces NF-kappa B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7, 813-820.
11. Ehtesham, M., Kabos, P., Gutierrez, M. A. R., Chung, N. H. C., Griffith, T. S., Black, K. L., and Yu, J. S. (2002) Induction of Glioblastoma Apoptosis Using Neural Stem Cell-mediated Delivery of Tumor Necrosis Factor-related Apoptosis-inducing Ligand. Cancer Res. 62, 7170-7174.
12. Ehtesham, M., Kabos, P., Kabosova, A., Neuman, T, Black, K. L., and Yu, J. S. (2002) The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res. 62, 5657-5663.
13. Emery, J. G., Mcdonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., Diprinzio, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C., and Young, P. R. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 273, 14363-14367.
14. Fulda, S., Wick, W., Weller, M., and Debatin, K. -M. (2002) Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nature Medicine. 8, 808-815.
15. Griffith, T. S., Anderson, R. D., Davidson, B. L., Williams, R. D., and Ratliff, T. L. (2000) Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol. 165, 2886-2894.
16. Griffith, T. S., and Broghammer, E. L. (2001) Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther. 4, 257-266.
17. Hao, C., Song, J. H., Hsi, B., Lewis, J., Song, D. K., Petruk, K. C., Tyrrell, D. L., and Kneteman, N. M. (2004) TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 64, 8502-8506.
18. Harrington, K., Alvarez-Vallina, L., Crittenden, M., Gough, M., Chong, H., Diaz, R. M., Vassaux, G., Lemoine, N., and Vile, R. (2002) Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther. 13, 1263-1280.
19. Hasegawa, H., Yamada, Y., Harasawa, H., Tsuji, T., Murata, K., Sugahara, K., Tsuruda, K., Ikeda, S., Imaizumi, Y., Tomonaga, M., Masuda, M., Takasu, N., and Kamihira, S. (2005) Sensitivity of adult T cell leukaemia lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand. Br J Haematol. 128, 253-265.
20. Jin, H., Aiyer, A., Su, J., Borgstrom, P., Stupack, D., Friedlander, M., and Varner, J. (2006) A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovascula-ture. J Clin Invest. 116, 652-662.
21. Johnson, T. R., Stone, K., Nikrad, M., Yeh, T., Zong, W X., Thompson, C. B., Nesterov, A., and Kraft, A. S. (2003) The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL over-expressing cells. Oncogene. 22, 4953-4963.
22. Johnston, J. B., Kabore, A. F., Strutinsky, J., Hu, X., Paul, J. T, Kropp, D. M., Kuschak, B., Begleiter, A., and Gibson, S. B. (2003) Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene. 22, 8356-8369.
23. Kagawa, S., He, C., Gu, J., Koch, P., Rha, S. -J., Roth, J. A., Curley, S. A., Stephens, L. C., and Fang, B. (2001) Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 61, 3330-3338.
24. Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C, Macdonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., Zhu, Z., Hicklin, D., Wu, Y, Port, J. L., Altorki, N., Port, E. R., Ruggero, D., Shmelkov, S. V, Jensen, K. K., Rafii, S., and Lyden, D. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438, 820-827.
25. Laconi, E., Pani, P., and Farber, E. (2000) The resistance phenotype in the development and treatment of cancer. Lancet Oncol. 1, 235-241.
26. Lapidot, T., Dar, A., and Kollet, O. (2005) How do stem cells find their way home? Blood. 106, 1901-1910.
27. Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., Deforge, L., Schow, P., Hooley, J., Sherwood, S., Pai, R., Leung, S., Khan, L., Gliniak, B., Bussiere, J., Smith, C. A, Strom, S. S., Kelley, S., Fox, J. A., Thomas, D., and Ashkenazi, A. (2001) Differential hepatocyte toxicity of recombinant Apo2LATRAIL versions. Nat Med. 7, 383-385.
28. Leblanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., and Ashkenazi, A. (2002) Tumor-cell resistance to death receptor - induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med. 8, 274-281.
29. Leblanc, H. N., and Ashkenazi, A. (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10, 66-75.
30. Lee, J., Elkahloun, A. G., Messina, S. A., Ferrari, N., Xi, D., Smith, C. L., Cooper, R., Jr., Albert, P. S., and Fine, H. A. (2003) Cellular and genetic characterization of human adult bone marrow-derived neural stem-like cells: a potential antiglioma cellular vector. Cancer Res. 63, 8877-8889.
31. Lee, J., Hampl, M., Albert, P., and Fine, H. A. (2002) Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia (New York, N.Y.). 4, 312-323.
32. Lieber, A., He, C. Y., Meuse, L., Schowalter, D., Kirillova, I., Winther, B., and Kay, M. A. (1997) The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol. 71, 8798-8807.
33. Mariani, S. M., Matiba, B., Armandola, E. A., and Krammer, P. H. (1997) Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol. 137, 221-229.
34. Mathas, S., Lietz, A., Anagnostopoulos, I., Hummel, F., Wiesner, B., Janz, M., Jundt, F., Hirsch, B., Johrens-Leder, K., Vornlocher, H. P., Bommert, K., Stein, H., and Dorken, B. (2004) c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med. 199, 1041-1052.
35. Mitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y, Richardson, P., Schlossman, R., Hideshima, T, and Anderson, K. C. (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 98, 795-804.
36. Mouzakiti, A., and Packham, G. (2003) Regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Br J Haematol. 122, 61-69.
37. Muhlenbeck, F, Schneider, P., Bodmer, J. L., Schwenzer, R., Hauser, A., Schubert, G., Scheurich, P., Moosmayer, D., Tschopp, J., and Wajant, H. (2000) The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem. 275, 32208-32213.
38. Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., Chen, J., Hentschel, S., Vecil, G., Dembinski, J., Andreeff, M., and Lang, F E (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 65, 3307-3318.
39. Nakata, S., Yoshida, T., Horinaka, M., Shiraishi, T., Wakada, M., and Sakai, T. (2004) Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene. 23, 6261-6271.
40. Pan, G., Ni, J., Wei, YF, Yu, G., Gentz, R., and Dixit, V. M. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277, 815-818.
41. Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., and Dixit, V. M. (1997) The receptor for the cytotoxic ligand TRAIL. Science. 276, 111-113.
42. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenazi, A. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 271, 12687-12690.
43. Pollack, I. F, Erff, M., and Ashkenazi, A. (2001) Direct stimulation of apoptotic signalling by soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clinical Cancer Research. 7, 1362-1369.
44. Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., and Kohn, K. W. (2004) Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 23, 2934-2949.
45. Quesenberry, P. J., Colvin, G., and Abedi, M. (2005) Perspective: fundamental and clinical concepts on stem cell homing and engraftment: a journey to niches and beyond. Exp Hematol. 33, 9-19.
46. Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., Goddard, A. D., Godowski, P., and Ashkenazi, A. (1997) Control of TRAIL-induced apoptosis by a family of signalling and decoy receptors. Science. 277, 818-821.
47. Studeny, M., Marini, F. C., Champlin, R. E., Zompetta, C., Fidler, I. J., and Andreeff, M. (2002) Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 62, 3603-3608.
48. Studeny, M., Marini, F. C., Dembinski, J. L., Zompetta, C., Cabreira-Hansen, M., Bekele, B. N., Champlin, R. E., and Andreeff, M. (2004) Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 96, 1593-1603.
49. Verfaillie, C. M. (1998) Adhesion receptors as regulators of the hematopoietic process. Blood. 92, 2609-2612.
50. Wajant, H. (2003) Death receptors. Essays Biochem. 39, 53-71.
51. Wajant, H., Moosmayer, D., Wuest, T., Bartke, T., Gerlach, E., Schonherr, U., Peters, N., Scheurich, P., and Pfizenmaier, K. (2001) Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene. 20, 4101-4106.
52. Walczak, H., Degli-Esposti, M. A., Johnson, R. S., Smolak, P. J., Waugh, J. Y., Boiani, N., Timour, M. S., Gerhart, M. J., Schooley, K. A., Smith, C. A., Goodwin, R. G., and Rauch, C. T. (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. Embo J. 16, 5386-5397.
53. Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R. G., Rauch, C. T., Schuh, J. C., and Lynch, D. H. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5, 157-163.
54. Wang, S., and El-Deiry, W S. (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 22, 8628-8633.
55. Waxman, D. J., and Schwartz, P. S. (2003) Harnessing apoptosis for improved anticancer gene therapy. Cancer Res. 63, 8563-8572.
56. Wen, J., Ramadevi, N., Nguyen, D., Perkins, C, Worthington, E., and Bhalla, K. (2000) Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood. 96, 3900-3906.
57. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., and Smith, C. A. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3, 673-682.
58. Wu, G. S., Burns, T. F., Zhan, Y., Alnemri, E. S., and El-Deiry, W S. (1999) Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59, 2770-2775.
59. Zhang, L., and Fang, B. (2004) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther.
60. Zheng, S. J., Wang, P., Tsabary, G., and Chen, Y. H. (2004) Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest. 113, 58-64.